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Abstract
Traditional medicines provide fertile ground for modern drug development, but first they must pass
along a pathway of discovery, isolation, and mechanistic studies before eventual deployment in the
clinic. Here, we highlight the challenges along this route, focusing on the compounds artemisinin,
triptolide, celastrol, capsaicin, and curcumin.
Traditional medicines continue to provide front-line pharmacotherapy for many millions of
people worldwide. Although their application is often viewed with skepticism by the Western
medical establishment, medicinal extracts used in ancient medical traditions such as Ayurveda
on the Indian subcontinent and traditional Chinese medicine (TCM) are a rich source of
therapeutic leads for the pharmaceutical industry.
The transformation of traditional medicines into modern drugs has its origins in the archetypal
examples of the antimalarial quinine and the antipyretic analgesic aspirin. The alkaloid quinine
was isolated in 1820 from the bark of several species of Cinchona, thought to have been used
by Peruvian Indians to suppress shivering and used since the 17th century in the treatment of
malarial fevers (Greenwood, 1992). Similarly, aspirin was derived from salicylic acid in the
bark of the willow tree (Salix species), used traditionally to treat fever and inflammation in
many cultures worldwide for at least four millennia (Mahdi et al., 2006). The successes of these
two early “blockbuster” drugs set the stage for ongoing drug discovery efforts from traditional
medicines.
Compounds derived from medicinal extracts are appealing for several reasons (Schmidt et al.,
2007). They are often stereochemically complex, multi- or macrocyclic molecules with limited
likelihood of prior chemical synthesis, and they tend to have interesting biological properties.
But perhaps most importantly, parent extracts have been “clinically” tested in their traditional
milieu, in some cases over millennia.
Despite these advantages, the path from traditional medicine to Western pharmaceutical is
fraught with challenges. Here, we discuss the challenges of each of the four steps in this pipeline
(see Figure 1): Western “discovery” of a traditional medicine, isolation and/or synthesis of the
active component, elucidation of the molecular mechanism, and development as a
pharmaceutical. We focus on five interesting and timely examples derived from traditional
medicines in varied therapeutic classes, each at a different stage in the development process,
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The antimalarial artemisinin (and derivatives) represents one of the greatest recent clinical
success stories arising from a traditional medicine, echoing the success of quinine two centuries
earlier. Artemisinin (see Figure 1) is derived from Artemisia annua L., the sweet wormwood
(qinghao), a shrub first documented in TCM in 168 BCE as a hemorrhoid treatment (Liu et al.,
2006). Since at least the fourth century CE, it has been used in the treatment of fever attributed
to malaria. This long history of use prompted Chinese researchers to seek the active antimalarial
principle; artemisinin was isolated and its structure determined in the mid 1970s (Liu et al.,
2006).
Artemisinin, an endoperoxide sesquiterpene lactone with a complex polycyclic ring structure,
is modified by Fe2+ ions to structures containing carbon-centered free radicals. Given that the
intracellular environment of the Plasmodium malaria parasite is rich in this ion from heme,
these radicals are currently thought to be responsible for artemisinin’s antimalarial activity.
The classic method of cell fractionation after treatment with radiolabeled artemisinin has
identified numerous cellular constituents alkylated by artemisinin (Asawamahasakda et al.,
1994); the strongest validated target for artemisinin is PfATP6, the Plasmodium sarco-
endoplasmic reticulum Ca2+ ATPase (SERCA), which is inhibited by artemisinin (Eckstein-
Ludwig et al., 2003).
Clinical studies, initiated in the 1970s prior to any mechanistic insights into artemisinin
function, demonstrated that artemisinin and its derivatives are powerful antimalarials. They
have proved particularly effective for treating severe malaria and, in combination with
traditional antimalarials, for combatting Plasmodium drug resistance. Combination therapies
containing artemisinin are now considered the treatment of choice for malaria in Asia, with
growing adoption in Africa (see Table 1 for information on clinical trials). Artemisinin may
also have efficacy against other parasites and as an anticancer compound, possibly acting via
antiangiogenic and proapoptotic mechanisms in the latter case (Efferth, 2007).
Despite these dramatic findings, widespread deployment of artemisinin has been hindered by
production difficulties. Although a dozen synthetic routes to artemisinin have been described,
all are complex and low yielding, rendering them economically unfeasible (Liu et al., 2006).
Synthetic chemistry has, however, offered semi-synthetic artemisinin derivatives with
improved solubility (such as sodium artesunate) and stability (such as artemether) (Efferth,
2007). Even a totally synthetic trioxolane compound RBX11160 (OZ277), inspired by the
trioxane endoperoxide moiety of artemisinin, has shown promise as an antimalarial
(Vennerstrom et al., 2004).
Artemisinin for clinical use is predominantly produced naturally in A. annua plants. Despite
efforts to maximize agricultural production, the artemisinin content in plant extracts varies
widely due to environmental conditions: 0.01%–0.8% dry weight (Efferth, 2007). This in turn
makes the drug itself expensive—particularly problematic for an antimalarial, which is needed
in large quantities in many poorer countries. Cell and plantlet cultures are an appealing
alternative source of this compound as they can be grown under much more closely controlled
conditions than whole plants. Indeed, useful yields of the compound can be produced by
feeding cultures artemisinin precursors (Liu et al., 2006). An alternative approach is the genetic
engineering of A. annua itself. The plant has proven genetically tractable: Several of the
isoprenoid biosynthetic enzymes necessary for artemisinin production have been cloned, and
A. annua can be successfully transformed with Agrobacterium tumefaciens to over-express
key biosynthetic genes (Liu et al., 2006).
Perhaps the most promising strategy is the use of microbes to produce artemisinin. In a triumph
of genetic engineering, Ro et al. combined genetic activation of the endogenous mevalonate
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isoprenoid synthesis pathway with introduction of A. annua genes to produce artemisinic acid
in the budding yeast Saccharomyces cerevisiae (Ro et al., 2006). This precursor compound,
which can be readily converted to artemisinin in the laboratory, is secreted in large quantities
from the yeast. Such creative strategies, leveraging the power of genetics and in vivo
biochemistry, can provide a valuable counterpart to synthetic chemistry and natural sources in
the production of natural product medicines.
Triptolide and Celastrol: Harnessing the Power of the Thunder God Vine
Trypterygium wilfordii Hook F., the “thunder god vine” (lei gong teng), is another TCM. This
vine has been used traditionally for the treatment of arthritis and other diseases, and it is the
source of several biologically active secondary metabolites (Tao and Lipsky, 2000). Some of
its TCM uses might rely on the presence of multiple active components, and clinical studies
have been performed on extracts of the plant (Table 1), rather than on a single compound (Tao
and Lipsky, 2000). However, substantial work has focused on two major bioactive constituent
compounds: triptolide and celastrol (Figure 1).
Triptolide is a diterpenoid epoxide with a staggering variety of documented cellular effects.
Along with anti-inflammatory activity, it shows anticancer, immunosuppressive, and
antifertility effects (Qiu and Kao, 2003). It was isolated in 1972, and several synthetic routes
have been described since then (Yang et al., 1998 and references therein). Like artemisinin,
however, triptolide is currently derived from its plant of origin with low yield: 6–16 ng/g in
one study (Brinker and Raskin, 2005). Little work has been done to investigate biotechnological
routes to triptolide production, which are important to reduce reliance on the natural source.
Moreover, continued development of derivatives of triptolide such as the succinyl sodium salt
PG490-88 will be valuable to improving the solubility and side-effect profile of this compound
(Tao and Lipsky, 2000).
Determination of triptolide’s cellular target has proven to be an even greater challenge. This
is not unusual: Many a promising therapeutic natural product has faltered when no clear-cut
mechanism of action could be identified. Although progression into the clinic without such
knowledge is possible, as was the case with artemisinin, a solid knowledge of molecular
mechanism (ideally at the structural, not just the molecular, level) allows medicinal chemists
to perform rational derivatization to improve affinity, specificity, pharmacokinetics, and
stability. Knowledge of mechanism can also potentially lead to more specific clinical trials
and, in cases like triptolide, completely new insights.
A large body of work describes triptolide’s inhibitory effects on transcription mediated through
NF-κB and NFAT (Qiu and Kao, 2003), but until recently, direct cellular targets were elusive.
Nonetheless, careful cell fractionation with [3H]-triptolide enabled identification of the Ca2+
channel polycystin-2 (encoded by the PKD2 gene) as a possible triptolidebinding protein
(others also likely exist) (Leuenroth et al., 2007). PKD2 or the gene encoding its activator,
PKD1, causes polycystic kidney disease (PKD) when mutated because entry of Ca2+ ions is
essential for growth arrest of epithelial cells forming the kidney tubule. Because triptolide
activates opening of the polycystin-2 channel, it could potentially complement loss of PKD1.
This is the case in a mouse model of polycystic kidney disease in which the mice lack Pkd1
(Leuenroth et al., 2007). Thus, this calcium-dependent activity of triptolide, which is unrelated
to its transcriptional repression activity (Leuenroth and Crews, 2005), opens a new therapeutic
avenue for pursuing triptolide, in addition to its effects on the immune and reproductive systems
and in cancer.
Highlighting the complexity of plant extracts, the pentacyclic triterpene celastrol (Figure 1) is
structurally a very different component of T. wilfordii with a divergent therapeutic profile.
Celastrol (also known as tripterine) is extracted in small quantities from T. wilfordii or other
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members of the Celastraceae (bittersweet) family. To our knowledge, no total synthesis or
alternative production routes have been reported.
Although not yet tested as a single agent in humans (Table 1), celastrol has shown promise as
an anti-inflammatory compound in animal models of arthritis, lupus, amyotrophic lateral
sclerosis, and Alzheimer’s disease (Sethi et al., 2007 and references therein). It also has
antiproliferative effects against numerous cancer cell lines. Several molecular mechanisms
have been identified for these effects, including gene expression modulation likely mediated
through inhibition of NF-κB via TAK1 and IκBα kinase (Sethi et al., 2007 and references
therein), proteasome inhibition, topoisomerase II inhibition, and heat shock response activation
(Hieronymus et al., 2006 and references therein). Nonetheless, direct targets remain elusive.
As celastrol and triptolide move into human studies, it will be vital not only to better understand
their mechanisms of action but also to investigate any potential synergistic effects of the two
compounds, both at the cellular and organismal levels.
Capsaicin: Painless for Some?
Used worldwide, the alkaloid capsaicin is the main cause of the “hot” sensation associated with
chili peppers, members of the genus Capsicum. Beyond their widespread use as a spice, chili
peppers were used in the Americas by the Aztecs and Tarahumara Indians as a remedy for
coughs and bronchitis. Similar uses plus anti-inflammatory and gastrointestinal applications
were adopted in India after the Portuguese imported chili peppers in the late 15th century. In
Africa, they are traditionally used internally and externally as antiseptics (Dasgupta and
Fowler, 1997). However, modern usage of capsaicin is focused on the treatment of various
types of pain (see below) and also in the treatment of detrusor hyperreflexia, a form of urinary
incontinence (Dasgupta and Fowler, 1997). High-dose oral capsaicin also has anticancer
properties in some animal model studies but seems to be a cancer promoter in others.
Compared with artemisinin, triptolide, and celastrol, capsaicin is chemically quite simple
(Figure 1). It was purified and named in the 19th century and first synthesized in the 1920s
(Dasgupta and Fowler, 1997). But the widespread cultivation of Capsicum makes synthesis
unnecessary, as large quantities of capsaicin can easily be extracted from readily available
peppers.
The mechanism of capsaicin in pain induction has been the topic of much neurophysiological
research (Cortright et al., 2007). Capsaicin, along with thermal heat, directly activates
nociceptors in the skin, the sensory neurons responsible for the sensation of pain, with the
subsequent release of the neurotransmitter substance P. Capsaicin’s therapeutic effect on pain
is due to the desensitization and eventual destruction of nociceptors following repeated
capsaicin exposure. In a classic example of expression cloning, Caterina et al. identified the
capsaicin receptor (Caterina et al., 1997). Capsaicin was known to cause Ca2+ ion influx into
nociceptors, so these authors transfected a nociceptor cDNA library into nonexcitable HEK293
cells and screened for capsaicin-dependent Ca2+ ion influx. The receptor they cloned, now
known as TRPV1, is a Ca2+ ion channel that also responds to, and integrates, signals from
piperine (the irritant in black pepper), protons, and other noxious stimuli (Caterina et al.,
1997).
The cloning of TRPV1 kick started the field of pain receptor pharmacology. Numerous
pharmaceutical companies are developing both TRPV1 antagonists (to block nociception
directly) and agonists (to desensitize nociceptors, as with capsaicin) (Immke and Gavva,
2006). Resiniferatoxin, another traditional medicine from the latex of Euphorbia resinifera, is
one such agonist with higher potency than capsaicin (Immke and Gavva, 2006). Efforts
continue to create TRPV1 agonists with better skin permeation and lacking the distinctive side
effect of a burning sensation on application.
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Capsaicin itself has been used clinically with moderate success as a topical treatment for the
pain of rheumatoid and osteoarthritis, psoriasis, diabetic neuropathy, and postherpetic
neuralgia (Table 1), but herein lies the particular challenge with this molecule: The chronic
pain disorders are notoriously idiosyncratic, and not all patients or all pain syndromes respond
to capsaicin (Immke and Gavva, 2006). The somewhat vague and diffuse traditional uses of
this compound offer little assistance here, unlike artemisinin, for instance. Thus, testing for
capsaicin efficacy is a matter of clinical trial and error, largely undermining the “tried and true”
advantage of a traditional medicine. The major clinical advantage that capsaicin holds over
other unrelated pain drugs under development is its approved status as a foodstuff.
Curcumin: Awaiting Targets and Outcomes
Like capsaicin, the polyphenol curcumin (Figure 1) is best known as a spice constituent: It is
the yellow pigment component of the curry spice turmeric (Curcuma longa, known as haldi
in Hindi). It is also, however, a drug used in Ayurveda and TCM in the treatment of diseases
as diverse as rheumatism, fever, intestinal disorders, trauma, and amenorrhea (see the Analysis
by S. Singh on page 765 of this issue). Modern research has attributed anti-inflammatory,
immunomodulatory, antimalarial, and anticancer effects to this multitalented compound
(Aggarwal et al., 2007).
Like capsaicin, synthesis of curcumin is trivial and was first reported in 1910, but sufficient
quantities of curcumin for therapeutic use are available from the spice. This is particularly
important as low bioavailability of the parent compound coupled with rapid intestinal
metabolism dictates large doses for clinical use (Sharma et al., 2005); derivatization of the
natural product is actively being pursued.
Given its pleiotropic clinical effects, it is perhaps not surprising that curcumin has documented
effects on countless intracellular signaling pathways. Its anti-inflammatory action can be
attributed largely to its inhibition of NF-κB activity, COX-2 and 5-LOX expression, and
cytokine release (Aggarwal et al., 2007). Curcumin may directly target IκBα kinase to block
NF-κB. It also binds to a number of other proteins, including thioredoxin reductase, several
kinases, and several receptors (Aggarwal et al., 2007). The challenge here, then, as with many
other natural products, is deciphering which of these targets is mechanistically valid for which
biological activity. With such a broad spectrum of potential targets and activities described for
curcumin, this is no easy task. Synthesis of derivatives that selectively ablate certain cellular
and/or therapeutic effects is one possible route to tease apart this mechanism-function
conundrum, perhaps in concert with radiolabeled fractionation experiments (as described
above) or affinity chromatography with immobilized curcumin.
The very versatility that makes curcumin appealing has also limited its rigorous clinical testing:
There are wide-ranging efficacy reports, but most are based on preclinical, anecdotal, or pilot
studies rather than on randomized, placebo-controlled, double-blind trials (Hsu and Cheng,
2007). Activity has been reported in several inflammatory and autoimmune diseases and
numerous cancers, both as a preventative agent and treatment, alone or in combination (Hsu
and Cheng, 2007). The relative ease and rapid payoff of undertaking preclinical or pilot studies,
compared to rigorous clinical trials, has slowed the formal validation of curcumin. This is
confounded by limited pharmaceutical company interest because curcumin itself is not
patentable (although synthetic methods, derivatives, and pharmaceutical formulations are) and
by the perception that, as a foodstuff, curcumin is more a nutraceutical (perhaps a dietary cancer
preventative) than a traditional drug. This perception can only be changed by clinical studies
showing successful disease treatment with curcumin. Phase I studies have documented
tolerance up to 8000 mg/day, allowing a large dose-response range to be tested in phase II
studies, several of which are underway for the treatment of cancer, psoriasis, and Alzheimer’s
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disease (Table 1) (Hsu and Cheng, 2007). We must await the outcomes of these studies before
curcumin can be validated as a pharmaceutical.
Ongoing Challenges
An effective drug should be facile and economical to produce and deliver, should display
favorable absorption, distribution, metabolism, excretion, and toxicity (ADMET)
characteristics, and should treat the targeted disease with specificity and efficacy. Traditional
medicines, as with other natural products, can offer powerful leads for therapeutic development
because (unlike synthetic libraries) they already have documented effects on the organism.
However, the process from plant to product is a slow one. Despite the oft-shared limitations
noted here, these five examples of traditional medicines are exceptional in the extent to which
they have been studied and the success they have achieved in the clinic; countless other
promising compounds wallow in obscurity.
The challenges are formidable (Figure 1): Ethnopharmacologists must identify a medicine, its
uses, and active components. These efforts are urgent, as traditional knowledge— and
traditional plant species—are being lost at an alarming rate. Chemists must then synthesize the
compound using a cost-effective method or develop alternative processes such as cell culture
or transgenesis to enable useful-scale production. Despite continuing advances in synthetic
chemistry, the very complexity of many natural products that is responsible for their desirable
biological function can make production difficult.
With a reliable supply of compound available, biologists can then identify and validate cellular
targets and mechanisms of action. New tools are sorely needed for this particularly daunting
challenge, such as methods that compare the phenotypic or gene expression profiles induced
by a small molecule to those induced by known compounds (Hieronymus et al., 2006) or
chemical enhancer/suppressor screens. Development of in silico tools to “dock” small
molecules with protein structures to provide models for testing in vitro will likely come into
their own with advances in structural genomics, as sufficient computational power becomes
available.
Ideally with a mechanism in hand, clinicians must then test the compound in the disease of
interest (Table 1) while keeping an open mind for unexpected therapeutic activities and
working with medicinal chemists to produce derivatives with improved ADMET properties.
Finally, regulatory approval must be obtained, as with all drugs. This is particularly problem-
atic if the active principle is an extract or mixture, rather than an isolated compound; the U.S.
Food and Drug Administration has been understandably reluctant to approve multiple-agent
drugs until recently (Schmidt et al., 2007). Only in 2006 was the first such drug approved:
Polyphenon E (MediGene), a topical antiviral prepared from catechins extracted from green
tea (Camellia sinensis).
Artemisinin, triptolide, celastrol, capsaicin, and curcumin are “poster children” for the power
and promise of turning traditional medicines into modern drugs. However, their stories
highlight the ongoing interdisciplinary research efforts that continue to be necessary to realize
the pharmaceutical potential of traditional therapeutics.
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Figure 1. The Route from Traditional Medicine to Modern Drug
Shown are five traditional medicines—artemisinin, triptolide, celastrol, capsaicin, and
curcumin—and the points in the pathway from ancient remedy to modern drug where they face
the biggest hurdles.
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Table 1
Five Traditional Medicines in Clinical Trials
Clinical Trials
Compound Disease Number Principal Sponsors
Artemisinin Malaria 81 31 charities, institutes, universities, and companies based in
Australia, Austria, Belgium, Colombia, Ethiopia, France, Gambia,
Germany, Ghana, Guinea-Bissau, the Netherlands, Papua New
Guinea, South Africa, Sudan, Sweden, Switzerland, the United
Kingdom, and the USA; and working in numerous Asian, African,
and South American locations
Cytomegalovirus infection 1 Hadassah Medical Organization, Israel





Rheumatoid arthritis 1 National Institute of Arthritis and Musculoskeletal and Skin
Diseases, MD, USA
Capsaicin Chronic pain 13 NeurogesX, CA, USA; AlgoRx Pharmaceuticals, NJ, USA
Postoperative pain 5 National Institute of Dental and Craniofacial Research, MD, USA;
AlgoRx Pharmaceuticals, NJ, USA
Radiation-induced mucositis 1 North Central Cancer Treatment Group, MN, USA
Alopecia areata 1 University of Minnesota
Morton’s neuroma 1 AlgoRx Pharmaceuticals
Osteoarthritis 1 Khon Kaen University
Interstitial cystitis 1 National Institute of Diabetes and Digestive and Kidney
Diseases,MD,USA
Curcumin Colon cancer 6 Chao Family Comprehensive Cancer Center, CA, USA; Tel-Aviv
Sourasky Medical Center, Israel; Johns Hopkins University, MD,
USA; University of Michigan Comprehensive Cancer Center, USA;
University of Pennsylvania, USA; University of Medicine and
Dentistry, NJ, USA
Pancreatic cancer 3 Rambam Medical Center, Israel; M.D. Anderson Cancer Center,
TX, USA; Tel-Aviv Sourasky Medical Center, Israel




1 Hadassah Medical Organization, Israel
Multiple myeloma 1 M.D. Anderson Cancer Center,TX,USA
Psoriasis 1 University of Pennsylvania,USA
Cystic fibrosis 1 Seer Pharmaceuticals,CT,USA
Includes registered, open, closed, terminated, and completed trials of these compounds, parent extracts, or derivatives. For details see
www.clinicaltrials.gov. Data current as of August 21, 2007.
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